Article

There is growing evidence of a preventive effect of Rituximab (RTX) in
neuromyelitis optica spectrum disorders (NMO-SD). This monoclonal antibody
against CD20 is becoming the most widely used preventive therapy in NMO-SD, as a
first-line therapy or as a rescue therapy. Nevertheless, considerable
heterogeneity still exists concerning the pre-treatment work-up, the vaccinations
required before and under treatment, the number and dosage of infusions,
prevention of the risk of infusion-related reactions, prevention of infections
under treatment, and frequency of therapeutic cycles. Thanks to a collaborative
work among NMO-SD experts belonging to the NOMADMUS project, we provide here
recommendations for all these topics concerning RTX use in NMO-SD.
CI - Copyright (c) 2018 Elsevier Masson SAS. All rights reserved.

Langue : ANGLAIS